Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Development of First in Class DNA-Zip Code Drug Conjugate (ZDC) in Multiple Myeloma

Andrey Pisarev, Munevver Cinar, Lourdes Martinez-Medina, Deon B. Dixie, Li Feng, Pavan Puvvula, Stephen Chang, Leon Bernal-Mizrachi

Blood (2023) 142 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2023-188644

Published: 2023

Journal Articles

Evaluation of a Prognostic 23-Gene Expression Panel in a Set of 390 Multiethnic Hodgkin Lymphoma Patients

Blood (2023) 142 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2023-182906

Published: 2023

Journal Articles

EBV Prevalence and Overall Survival in the M ulti e thnic S tudy of H odgkin Lymphoma (MESH)

Blood (2023) 142 (Supplement 1): 6188.

https://doi.org/10.1182/blood-2023-182919

Published: 2023

Journal Articles

Association of Socioeconomic Status with Adherence, Progression Free and Overall Survival to Oral Agents in Multiple Myeloma Patients

W. Cliff Rutter, Elisea Avalos-Reyes, Will Cavers, Shivaani Prakash, Kjel Johnson, Leon Bernal-Mizrachi

Blood (2022) 140 (Supplement 1): 10065–10067.

https://doi.org/10.1182/blood-2022-160228

Published: 2022

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 7311–7312.

https://doi.org/10.1182/blood-2022-170062

Published: 2022

Journal Articles

Horizontal Gene Transfer in Multiple Myeloma and Development of a Non-Viral Gene Delivery System

Lourdes Martinez-Medina, Munevver Cinar, Bassel El-Rayes, Ganji Nagaraju, Jean-Michel Gries, Leon Bernal-Mizrachi

Blood (2021) 138 (Supplement 1): 3982.

https://doi.org/10.1182/blood-2021-154018

Published: 2021

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Jing C. Ye, Ravi Vij, Craig C. Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Jeffrey M. Switchenko, Sagar Lonial, Jonathan L. Kaufman

Blood (2021) 138 (Supplement 1): 2758.

https://doi.org/10.1182/blood-2021-153922

Published: 2021

Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons

Blood (2021) 138 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2021-150094

Published: 2021

Journal Articles

Cell Specific Recognition and Capture of Ctdna in Multiple Myeloma

Munevver Cinar, Badri Vardarajan, Neil Anthony, Bassel El-Rayes, Ganji Nagaraju, Lourdes Martinez-Medina, Jean-Michel Gries, Leon Bernal-Mizrachi

Blood (2021) 138 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2021-153857

Published: 2021

Journal Articles

Trasposon Mediated Horizontal Gene Transfer (T-HGT) of Circulating Tumor DNA Reshapes MM Clonal Architecture

Munevver Cinar, MD, Steven Flygare, Marina Mosunjac, Ganji Nagaraju, Dongkyoo Park, Sheff Faith, Debra Saxe, PhD, Leon Bernal-Mizrachi, MD

Blood (2019) 134 (Supplement_1): 3065.

https://doi.org/10.1182/blood-2019-126699

Published: 2019

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 3188.

https://doi.org/10.1182/blood-2019-131223

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Craig E. Cole, MD, Leonard Heffner, MD, Ajay K Nooka, MDMPH, Ravi Vij, MBBS, Nyaya Kelkar, Akshata Sridhar, Munevver Cinar, MD, Zhengjia Chen, PhD, Zhao Chang, PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2018-99-119337

Published: 2018

Journal Articles

Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF-κB Pathway

Munevver Cinar, MD, Hsiao-Rong Rong, Iloabueke Chineke, MD, Abner Louissaint, Jr., MD PhD, Jennifer Rose Chapman-Fredricks, MD, Francisco Vega, MD PhD, Clifford James Gunthel, MD, Cassandra Love, Marina Mosunjac, Christopher R Flowers, MDMS, Sandeep Dave, MD, Izidore S. Lossos, MD, Leon Bernal-Mizrachi, MD

Blood (2018) 132 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2018-99-118351

Published: 2018

Journal Articles

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Blood (2018) 132 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2018-99-114281

Published: 2018

Journal Articles

Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths

Blood (2017) 130 (Supplement 1): 5667.

https://doi.org/10.1182/blood.V130.Suppl_1.5667.5667

Published: 2017

Journal Articles

Smoothened Stabilizes and Protects TRAF6 from Proteosomal Degradation: A Novel Non-Canonical Role of Smoothened with Implications in Lymphoma Biology

Changju QU, MDPhD, Amineh Vaghefi, MD, Kranthi Kunkalla, MS, Jennifer R Chapman, MD, Yadong Liu, MD, Marzenna Blonska, PhD, Juan Pablo Alderuccio, MD, Leon Bernal-Mizrachi, MD, Izidore S Lossos, MD, Ralf Landgraf, PhD, Francisco Vega, MD PhD

Blood (2017) 130 (Supplement 1): 646.

https://doi.org/10.1182/blood.V130.Suppl_1.646.646

Published: 2017

Journal Articles

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

Jenny Zhang, BSc, Anupama Reddy, PhD, Nicholas Davis, BSc, Andrea Moffitt, PhD, Cassandra Love, Alexander Waldrop, PhD, Sirpa Leppa, MD, Annika Pasanen, MD, Leo Meriranta, MS, Marja-Liisa Karjalainen-Lindsberg, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Anne Ortved Gang, Estrid Hogdall, PhD, Tayla Heavican, Waseem Lone, PhD, Javeed Iqbal, MSc, PhD, Guojie Li, PhD, So Young Kim, PhD, Jane Healy, MD PhD, Kristy L. Richards, MD PhD, Yuri Fedoriw, MD, Leon Bernal-Mizrachi, MD, Jean L. Koff, MD, Ashley D. Staton, MD, Christopher Flowers, MD, Ora Paltiel-Clarfield, Neta Goldschmidt, MD, Maria Calaminici, MD PhD, Andrew James Clear, BSc, John G. Gribben, MDDSc FMedSci, Evelyn Nguyen, Magdalena Czader, MD PhD, Sarah L. Ondrejka, MD, Angela Collie, MD PhD, Eric D. Hsi, MD, Eric Tse, MBBS, PhD FRCP, FRCPath, Rex Au-Yeung, Yok-Lam Kwong, Gopesh Srivastava, William Choi, MBBS,MRCP, Andrew M Evens, DO,MSc, Monika Pilichowska, MD PhD, Manju Sengar, MD DM, Nishitha Reddy, MD MSCI, MBBS, Shaoying Li, MD, Amy Chadburn, MD, Leo I. Gordon, MD, Elaine S. Jaffe, MD, Rachel Rempel, Tiffany Tzeng, Tushar Dave, Lanie Happ, Deepthi Rajagopalan, Jyotishka Datta, David Dunson, Sandeep Dave, MD

Blood (2017) 130 (Supplement 1): 37.

https://doi.org/10.1182/blood.V130.Suppl_1.37.37

Published: 2017

Journal Articles

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants

Zhaohui Du, M.S., Niels Weinhold, PhD, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, M.S., Victor Hom, M.S., Sikander Ailawadhi, Ajay K. Nooka, MDMPH, Seema Singhal, MD, Karen Pawlish, Sc.D, M.P.H, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Donglei Hu, M.S., John Graff, PhD, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, John David Carpten, PhD, Graham Casey, PhD, Victoria L. Stevens, PhD, Rick Kittles, PhD, Goodman Phyllis, M.S., Anselm Hennis, MB;BS, MSc., PhD DLSHTM, FRCP, FACP, Eric A. Klein, MD, Barbara Nemesure, Benjamin A. Rybicki, Janet Stanford, John Witte, PhD, Christine B. Ambrosone, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Andrew Olshan, Wei Zheng, MD PhD, Jennifer J. Hu, Regina Ziegler, PhD, M.P.H., Sarah J. Nyante, Elisa Bandera, Sue Ann Ingles, PhD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Michael Tomasson, MD, Mark A. Fiala, BS, Howard Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Loic Le Marchand, MD, PhD, Kenneth C Anderson, MD, Elad Ziv, MD, Brian C.-H. Chiu, PhD, David Conti, PhD, Daniel Stram, PhD, Ravi Vij, MDMBA, Leon Bernal-Mizrachi, MD, Jeffrey A Zonder, MD, Gareth J. Morgan, MD PhD, Carol Ann Huff, MD, Robert Z. Orlowski, MD PhD, Sagar Lonial, MD, Christopher A. Haiman, PhD, Wendy Cozen, DO,MPH

Blood (2017) 130 (Supplement 1): 3058.

https://doi.org/10.1182/blood.V130.Suppl_1.3058.3058

Published: 2017

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

NARROW

Development of First in Class DNA-Zip Code Drug Conjugate (ZDC) in Multiple Myeloma

Evaluation of a Prognostic 23-Gene Expression Panel in a Set of 390 Multiethnic Hodgkin Lymphoma Patients

EBV Prevalence and Overall Survival in the M ulti e thnic S tudy of H odgkin Lymphoma (MESH)

Association of Socioeconomic Status with Adherence, Progression Free and Overall Survival to Oral Agents in Multiple Myeloma Patients

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Horizontal Gene Transfer in Multiple Myeloma and Development of a Non-Viral Gene Delivery System

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Cell Specific Recognition and Capture of Ctdna in Multiple Myeloma

Trasposon Mediated Horizontal Gene Transfer (T-HGT) of Circulating Tumor DNA Reshapes MM Clonal Architecture

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF-κB Pathway

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths

Smoothened Stabilizes and Protects TRAF6 from Proteosomal Degradation: A Novel Non-Canonical Role of Smoothened with Implications in Lymphoma Biology

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only